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Abstract—Recognition of biomedical entities from literature
is a challenging research focus, which is the foundation for
extracting a large amount of biomedical knowledge existing
in unstructured texts into structured formats. Using the se-
quence labeling framework to implement biomedical named
entity recognition (BioNER) is currently a conventional method.
This method, however, often cannot take full advantage of the
semantic information in the dataset, and the performance is
not always satisfactory. In this work, instead of treating the
BioNER task as a sequence labeling problem, we formulate
it as a machine reading comprehension (MRC) problem. This
formulation can introduce more prior knowledge utilizing well-
designed queries, and no longer need decoding processes such as
conditional random fields (CRF). We conduct experiments on six
BioNER datasets, and the experimental results demonstrate the
effectiveness of our method. Our method achieves state-of-the-
art (SOTA) performance on the BC4CHEMD, BC5CDR-Chem,
BC5CDR-Disease, NCBI Disease, BC2GM and JNLPBA datasets,
with F1-scores of 92.38%, 94.19%, 87.36%, 90.04%, 84.98% and
78.93%, respectively.
Index Terms—text mining, named entity recognition, NER,
machine reading comprehension, MRC
I. INTRODUCTION
Biomedical named entity recognition (BioNER) aims to
automatically recognize biomedical entities (e.g., chemicals,
diseases and proteins) in given texts. Effectively recognizing
biomedical entities is the prerequisite for extracting biomed-
ical knowledge deposited in unstructured texts, transforming
them into structured formats. Therefore, the BioNER task has
important research value.
Traditionally, BioNER methods usually depend on well-
designed feature engineering, i.e., the design of features using
various natural language processing (NLP) tools and domain
knowledge. Typical representatives of such models used in
the biomedical domain include DNorm [1], tmChem [2],
TaggerOne [3], Lou’s joint model [4], etc. Feature engineering,
however, relies heavily on domain-specific knowledge and
hand-crafted features. Furthermore, these features are both
model- and entity-specific. In recent years, neural networks
with automatic feature learning abilities have become prevalent
in NER tasks [5], [6]. For the biomedical domain, several neu-
ral network methods [7]–[12] have been proposed to recognize
biomedical entities. Within these methods, bidirectional long
short-term memory (BiLSTM) [13] is usually employed to
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learn vector representations of each word/token in a sentence,
and then as the input to conditional random fields (CRF) [14].
Very recently, language models (e.g., ELMo [15] and BERT
[16]) obtained state-of-the-art (SOTA) performance on many
NLP tasks. In the biomedical domain, Lee et al. [17] used
BioBERT (namely BERT pre-trained on biomedical corpora)
and the softmax function to recognize biomedical entities, and
their method achieved SOTA results on several biomedical
datasets. Compared with feature engineering methods, neu-
ral network methods have the ability to automatically learn
features and thus can achieve more competitive performance.
The existing methods usually formalize the BioNER task
into a sequence labeling problem, i.e., training a sequence
labeling model to assign a label to each token in a given se-
quence. However, the models mentioned above, i.e., BiLSTM-
CRF and BioBERT-Softmax, both cannot effectively learn the
semantic information in the sequence labeling framework. For
BiLSTM, its representation ability has certain deficiencies,
which limits the performance [17], [18]. For BioBERT, it is
difficult to effectively use the semantic information learned by
the final layer of BioBERT in the sequence labeling framework
[19].
Inspired by the current trend of formalizing NLP tasks into
machine reading comprehension (MRC) tasks [20]–[24], we
use BioBERT in the MRC framework to perform BioNER
(referred to BioBERT-MRC). In the MRC framework, each
biomedical entity type can be encoded by a language query
and identified by answering these queries. Take a sentence
“[Meloxicam]chemical - induced liver toxicity .” from the
BC5CDR-Chem dataset as an example. We can introduce more
prior knowledge by designing queries in the MRC frame-
work. Therefore, the original sentence can be formalized as
a sentence pair “[Meloxicam]chemical - induced liver toxicity
. Can you detect chemical entities like sodium or RA or
cannabis ?”, where ‘sodium’, ‘RA’ and ‘cannabis’ are chemical
entities and can be obtained from the BC5CDR-Chem dataset.
Compared with the sequence labeling framework, the MRC
framework essentially has the advantage of introducing prior
knowledge. More importantly, by converting the sequence
labeling problem into the MRC problem, we can make full
use of hidden representations of deep layers in BERT to learn
semantic information. This can overcome the deficiency of
existing methods and is more meaningful for BioNER tasks,
such as using BioBERT-MRC for transfer learning to further
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improve model performance.
We use BioBERT in the MRC framework to perform
BioNER tasks and conduct experiments on six datasets, i.e.,
BC4CHEMD [25], BC5CDR-Chem [26], BC5CDR-Disease
[26], NCBI Disease [27], BC2GM [28] and JNLPBA [29]
datasets. Our method achieves SOTA performance on all these
datasets. Moreover, we also analyze some typical layers of
BERT. The experimental results show that BioBERT-MRC
can effectively learn semantic information, thereby improv-
ing model performance. Finally, we further point out that
using BioBERT-MRC for transfer learning is possible to
obtain considerable performance improvement. This experi-
mental finding may be more meaningful for the development
of BioNER tasks. The code and datasets can be found at
https://github.com/CongSun-dlut/BioBERT-MRC.
II. RELATED WORK
A. Language Model
Word embeddings can use a large amount of unlabeled
data to learn the latent syntactic and semantic information
of words/tokens, and map these words/tokens into dense
low-dimensional vectors. In the past decade, several word-
embedding methods have been proposed, among which the
representative methods are Word2Vec [30], [31] and GloVe
[32]. Word2Vec employs the Skip-Gram model [30] to predict
surrounding words according to the current word/token or
utilizes the Continuous Bag-Of-Words (CBOW) model [31]
to model the current word/token based on the surrounding
context. GloVe [32] uses a specific weighted least squares
model that trains on global word-word co-occurrence counts,
and thus makes efficient use of statistics and considers both the
local and global features of the training corpus. However, the
word/token trained by these methods is mapped to a certain
vector. Therefore, word embeddings trained by these methods
can only model context-independent representations.
Recently, language models such as ELMo [15] and BERT
[16] have shown a considerable boost to NLP tasks. Unlike
traditional word embeddings such as Word2Vec and GloVe, the
embedding assigned to the word/token by the language model
depends on the context. Therefore, the same word/token can
have different representations in different contexts. ELMo [15]
leverages the concatenation of independently trained left-to-
right and right-to-left LSTM to model the contextual informa-
tion of the input sequence. BERT [16] employs Transformer
[33] to pre-train representations by jointly conditioning on
both left and right context in all layers. Because the great
success of BERT, it has gradually become a mainstream
method that using a large corpus to pre-train BERT and fine-
tuning it on the target dataset. Furthermore, the use of BERT
for transfer learning has also become a promising research
direction [34], [35].
B. Machine Reading Comprehension
The MRC methods [20]–[24] can extract answer spans from
the context through a given query. This task can be formalized
as two classification tasks, namely to predict the start and
end positions of the answer spans. In recent years, there has
been a trend of converting related NLP tasks into MRC tasks.
For example, McCann et al. [21] used the question answering
framework to implement ten different NLP tasks uniformly,
and all achieved competitive performance. For the NER task,
Li et al. [24] employed BERT to recognize entities from texts
in the MRC framework (in the general domain). To the best
of our knowledge, there is currently no specific research for
BioNER in the MRC framework. Our work focus specifically
on biomedical entities, which is significantly different from
Li’s work [24]. More importantly, we are the first to explore
the effect of different BERT layers on BioNER tasks in the
MRC framework. In addition, we point out that BERT may
achieve better BioNER performance by performing transfer
learning in the MRC framework.
III. METHODOLOGY
A. Task Definition
Given an input sentence X = {x1, x2, · · · , xN}, where
xi is the i-th word/token and N represents the length of the
sentence. The goal of NER is to classify each word/token in
X and assign it to a corresponding label y ∈ Y , where Y is a
predefined list of all possible label types (e.g., CHEMICAL,
DISEASE and PROTEIN). We formulate the NER task as an
MRC task and thus need to convert the labeling-style NER
dataset into a set of (Context, Query, Answer) triples. For
each label type y, we first constructed a query Qy = {q1, q2,
· · · , qM} for each sentence, where M represents the length of
the query. Then, we obtained the annotated entities xstart,end
according to the annotated labels Y , where xstart,end is a
substring of X and start ≤ end. For example, the sentence
from the BC5CDR-Chem dataset, “Meloxicam - induced liver
toxicity .”, its corresponding labels are “B O O O O O”.
According to the labels, we can obtain the entities and their
spans: ‘Meloxicam’0,0. Finally, we constructed the triple (X ,
Qy , xstart,end), which is exactly the (Context, Query, Answer)
triple that we need.
B. Construct Queries
Different from the query generation in the general domain,
e.g., Li et al. [24] utilized the annotation guideline notes as
references to construct queries, we used biomedical entities
from the training/development set of the target dataset to
construct queries. Table I lists some examples of the queries
TABLE I
EXAMPLE OF CONSTRUCTED QUERIES.
Entity type Query
CHEMICAL Can you detect chemical entities like chemical1 or
chemical2 or chemical3 ?
DISEASE Can you detect disease entities like disease1 or
disease2 or disease3 ?
PROTEIN Can you detect protein entities like protein1 or
protein2 or protein3 ?
Notes: chemicalx, diseasex and proteinx are biomedical entities,
which can be obtained from the training/development set of the target
dataset.
we constructed. We conducted experiments on three types of
biomedical entities (i.e., CHEMICAL/DRUG, DISEASE and
PROTEIN/GENE). The entity variables (such as chemical1,
chemical2 and chemical3) represent the annotated ones se-
lected randomly from the training/development set of the target
dataset. In this way, the queries can introduce more sufficient
prior knowledge to the model, thereby enhancing the model’s
ability to recognize biomedical entities.
C. Model Details
We exploited BERT [16] as our model backbone. In this
study, we need to recognize entities in the biomedical domain,
so we employed BioBERT [17] as the model weight. Figure 1
shows the BioNER task implemented in the MRC framework
using BERT. Firstly, the query Qy is concatenated with the
context X , forming the combined sequence {[CLS], x1, x2,
· · · , xN , [SEP], q1, q2, · · · , qM , [SEP]}, where ‘[CLS]’ and
‘[SEP]’ are special tokens. Then, the combined sequence is fed
into BERT, which can be defined by the following formulas:
h0i =Weti +Wb (1)
hli = Trm(h
l−1
i ) (2)
H = [hL1 ;h
L
2 ; · · · ;hLN ] ∈ RN×d (3)
where ti is the embedding of the i-th token, We, Wb are
parameters, L means the total number of layers for BERT,
l (1 ≤ l ≤ L) is the number for the current layer, and Trm
denotes the Transformer [33] block, including multi-head at-
tention layers, fully connected layers and normalization layers.
Furthermore, H is the output of BERT and N is the length of
the context. We simply dropped query representations because
they are not the target of the model prediction.
There are usually two strategies for choosing the span in the
MRC framework. The first is to employ two n-class classifiers
to respectively predict the start and end indexes, where n is
the length of the context. Because the function is calculated on
all tokens in the entire context, this strategy has the deficiency
that one input sequence can only output one span. The other
is to construct two binary classifiers. One is used to predict
whether the token is a start index, and the other is employed
to predict whether the token is an end index. This strategy
allows multiple start and end indexes to be output for a given
sequence, and therefore it has the potentials to identify all
target entities based on Qy .
In this study, we adopted the second strategy. Given the
representation matrix H output by BERT, the model first
predicts the probability of each token being a start index. The
formula is as follows:
Lstart = linear(HWstart) ∈ RN×2 (4)
where linear is a fully connected layer and Wstart is the
weight to learn. Each row of Lstart denotes a hidden repre-
sentation of each index, used to determine the starting position
of a target entity for a given query.
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E[SEP]
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Fig. 1. Using BERT to perform BioNER in the MRC framework.
The end index prediction process is similar to the start
index prediction process. To better predict the end index, we
designed two strategies:
Lend = linear(HWend) ∈ RN×2 (5)
or
Lend = linear(HWend; softmax(Lstart)) ∈ RN×2 (6)
where linear is a fully connected layer, Wend is the weight
to learn, and ‘;’ means the concatenation operation.
Then, by applying the argmax function to each row of Lstart
and Lend, we can obtain the predicted indexes that might be
the start or end positions, i.e., Istart and Iend:
Istart = {i | argmax(Listart) = 1, i = 1, 2, · · · , N} (7)
Iend = {j | argmax(Ljend) = 1, j = 1, 2, · · · , N} (8)
where the superscript i and j denote the i-th and j-th rows of
a matrix, respectively.
In context X , there could be multiple entities of the same
entity type. This means that multiple start/end indexes can
be predicted from one input sequence at one time. Because
the datasets we conducted experiments on are all flat NER
datasets, we further used the nearest match principle to match
the start and end indexes to obtain final answers. Specifically,
for the case where one end/start index corresponds to multiple
start/end indexes, only the nearest start/end index is matched.
D. Training and Test
At the training time, context X is paired with two label
sequences Ystart and Yend of length N representing the
ground-truth label of each token xi being the start/end index of
the biomedical entity. The loss function is defined as follows:
Lossstart = CE(Lstart, Ystart) (9)
Lossend = CE(Lend, Yend) (10)
Loss = (1− λ)Lossstart + λLossend (11)
where CE denotes the cross-entropy loss function and λ ∈
[0, 1] is a hyper-parameter used to control the overall training
objective. In this study, we set λ = 0.5 according to the
performance of the model on the development set.
At the test time, the start and end indexes are first separately
selected based on Istart and Iend. Then, the nearest match
principle is used to match the start/end indexes to obtain the
final answers.
IV. EXPERIMENTS
A. Datasets and Experimental Settings
Our method is evaluated on BC4CHEMD [25], BC5CDR
[26], NCBI-Disease [27], BC2GM [28] and JNLPBA [29]
datasets, all of which are pre-processed and provided by Lee et
al. [17]. Among these datasets, BC5CDR has two sub-datasets,
BC5CDR-Chem and BC5CDR-Disease, which are used to
evaluate chemical and disease entities, respectively. Because
most of the existing methods were evaluated on BC5CDR-
Chem and BC5CDR-Disease respectively, we did the same.
Table II lists the statistics of these datasets.
TABLE II
STATISTICS OF BIONER DATASETS.
Dataset Entity type No. annotations No. sentences
BC4CHEMD Chemical/Drug 79,842 89,679
BC5CDR-Chem Chemical/Drug 15,411 14,228
BC5CDR-Disease Disease 12,694 14,228
NCBI-Disease Disease 6,881 7,639
BC2GM Protein/Gene 20,703 20,510
JNLPBA Protein/Gene 35,460 22,562
Notes: Statistics are from Habibi et al. [7].
In the experiments, the original training and development
set were merged into a new training set. Then 10% of the
new training set was sampled as the validation set to tune
hyper-parameters. The test set was only used to evaluate the
model. Most existing works [3], [9]–[12], [17] pre-processed
data in this way, and we also followed this way. We used
BioBERTBASE v1.1 (+PubMed) [17] as the BERT weight. To
facilitate comparison with the baseline method, most of our
hyper-parameters are similar to those of Lee et al. [17], with
only a few hyper-parameters (e.g., training epochs) different.
The performance is measured with the F1-score (F1), which
attributes equal importance to precision (P ) and recall (R).
The formula is: F1 = 2PR/(P+R). Moreover, all significance
tests in this work are based on T-TEST.
B. Impact of Different MRC Strategies on Model Performance
In this work, we compared the impact of different MRC
strategies on model performance. First, we explored the impact
of different span strategies. As described in Section III.C, two
TABLE III
PERFORMANCE COMPARISON FOR DIFFERENT END INDEX STRATEGIES.
Dataset Model P(%) R(%) F1(%)
BC4CHEMD BioBERT-MRCa 93.15 90.89 92.01
BioBERT-MRCb 92.83 91.94 92.38
BC5CDR-Chem BioBERT-MRCa 94.20 93.87 94.04
BioBERT-MRCb 94.37 94.00 94.19
BC5CDR-Disease BioBERT-MRCa 88.20 87.03 87.61
BioBERT-MRCb 87.42 87.30 87.36
NCBI-Disease BioBERT-MRCa 88.62 91.67 90.12
BioBERT-MRCb 89.67 90.42 90.04
BC2GM BioBERT-MRCa 86.10 83.65 84.86
BioBERT-MRCb 86.05 83.94 84.98
JNLPBA BioBERT-MRCa 75.10 82.40 78.58
BioBERT-MRCb 75.97 82.13 78.93
Average BioBERT-MRCa 87.56 88.25 87.87
BioBERT-MRCb 87.72 88.29 87.98
Notes: BioBERT-MRCa denotes the end index prediction is designed on
equation 5, and BioBERT-MRCb presents the end index prediction is
designed on equation 6. The best scores are shown in bold.
TABLE IV
PERFORMANCE COMPARISON FOR DIFFERENT TYPES OF QUERIES.
Dataset Model P(%) R(%) F1(%)
BC4CHEMD BioBERT-MRC† 93.36 91.15 92.24
BioBERT-MRC‡ 93.25 91.08 92.16
BioBERT-MRC 92.83 91.94 92.38
BC5CDR-Chem BioBERT-MRC† 93.75 93.80 93.77
BioBERT-MRC‡ 93.45 94.02 93.73
BioBERT-MRC 94.37 94.00 94.19
BC5CDR-Disease BioBERT-MRC† 87.21 86.64 86.93
BioBERT-MRC‡ 88.06 86.53 87.29
BioBERT-MRC 87.42 87.30 87.36
NCBI-Disease BioBERT-MRC† 90.35 88.75 89.54
BioBERT-MRC‡ 90.31 90.31 90.31
BioBERT-MRC 89.67 90.42 90.04
BC2GM BioBERT-MRC† 86.15 83.62 84.87
BioBERT-MRC‡ 86.26 83.75 84.98
BioBERT-MRC 86.05 83.94 84.98
JNLPBA BioBERT-MRC† 74.60 82.79 78.48
BioBERT-MRC‡ 74.33 83.29 78.56
BioBERT-MRC 75.97 82.13 78.93
Notes: BioBERT-MRC† denotes the query is the simple query, and
BioBERT-MRC‡ represents the query using the none query. The best
scores are shown in bold.
end index strategies are designed for BioBERT-MRC. The per-
formance comparison is shown in Table III. BioBERT-MRCa
denotes the end index prediction is designed on equation 5, and
BioBERT-MRCb presents the end index prediction is designed
on equation 6. It can be seen that the F1-scores of these two
strategies are both competitive. This indicates the stability
of BioBERT-MRC. On average, compared with BioBERT-
MRCa, BioBERT-MRCb has a higher precision and thus
obtains a higher F1-score. This may be due to the introduction
of the start index information, leading to the model being able
to learn more span information. Because the higher average
F1-score of BioBERT-MRCb, in the experiments, we adopted
BioBERT-MRCb as the BioBERT-MRC model.
Then, we explored the impact of constructed queries. In-
tuitively, the more information a query contains, the better
its effect should be. Therefore, we constructed the queries as
described in Section III.B. Moreover, we further designed two
TABLE V
PERFORMANCE COMPARISON FOR DIFFERENT MODELS.
Dataset Model P(%) R(%) F1(%)
BC4CHEMD BioBERT-Softmax [17] 92.80 91.92 92.36
BioBERT-Softmax 92.66 91.69 92.17
BioBERT-CRF 92.67 91.32 91.99
BioBERT-BiLSTM-CRF 92.51 91.12 91.81
BioBERT-MRC 92.83 91.94 92.38
BC5CDR-Chem BioBERT-Softmax [17] 93.68 93.26 93.47
BioBERT-Softmax 92.64 94.39 93.51
BioBERT-CRF 93.30 93.82 93.56
BioBERT-BiLSTM-CRF 93.57 93.48 93.53
BioBERT-MRC 94.37 94.00 94.19
BC5CDR-Disease BioBERT-Softmax [17] 86.47 87.84 87.15
BioBERT-Softmax 85.04 88.02 86.50
BioBERT-CRF 85.97 87.43 86.70
BioBERT-BiLSTM-CRF 86.07 87.27 86.67
BioBERT-MRC 87.42 87.30 87.36
NCBI-Disease BioBERT-Softmax [17] 88.22 91.25 89.71
BioBERT-Softmax 86.97 91.04 88.96
BioBERT-CRF 86.66 90.00 88.30
BioBERT-BiLSTM-CRF 88.68 88.96 88.82
BioBERT-MRC 89.67 90.42 90.04
BC2GM BioBERT-Softmax [17] 84.32 85.12 84.72
BioBERT-Softmax 84.44 85.04 84.74
BioBERT-CRF 84.80 84.60 84.70
BioBERT-BiLSTM-CRF 83.61 85.57 84.58
BioBERT-MRC 86.05 83.94 84.98
JNLPBA BioBERT-Softmax [17] 72.24 83.56 77.49
BioBERT-Softmax 72.80 84.30 78.13
BioBERT-CRF 73.06 83.93 78.12
BioBERT-BiLSTM-CRF 72.65 83.24 77.58
BioBERT-MRC 75.97 82.13 78.93
Notes: The best scores are shown in bold.
types of queries to explore the impact of different queries:
• Simple query. Simple language query, i.e., “Can you de-
tect X-type entities ?”. For example, for the CHEMICAL
entity, the query is “Can you detect chemical entities ?”.
• None query. The query is designed as “none”.
Table IV illustrates the performance comparison for differ-
ent types of queries. BioBERT-MRC† and BioBERT-MRC‡
denote the situation where the query we constructed is a
simple query and none query, respectively. It can be seen
that the performance of BioBERT-MRC is superior to these
two models, which shows that using high-quality entities from
the training/development set as queries can improve model
performance.
C. MRC vs Sequence Labeling
In this work, we explored the effect of BERT in the MRC
framework and the sequence labeling framework in detail.
First, we compared the performance of BERT on BioNER in
the MRC framework and the sequence labeling framework.
Table V shows the performance comparison for different
models. BioBERT-Softmax, BioBERT-CRF and BioBERT-
BiLSTM-CRF are commonly used methods in the sequence
labeling framework. It can be seen that the performance of
these three methods is similar. On the BC4CHEMD dataset,
the performance of BioBERT-Softmax is superior to BioBERT-
CRF and BioBERT-BiLSTM-CRF. The reason may be that
the examples in the dataset are relatively long, while CRF
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[SEP]
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[SEP]
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(a) Attention heat map of the first layer.
[C
LS
]
M
el
##
ox
##
ica
##
m -
in
du
ce
d
liv
er
to
xi
cit
y .
[S
EP
]
Ca
n
yo
u
de
te
ct
ch
em
ica
l
en
tit
ie
s
lik
e
so
di
um o
r
RA o
r
ca
nn
ab
is ?
[S
EP
]
[CLS]
Mel
##ox
##ica
##m
-
induced
liver
toxicity
.
[SEP]
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[SEP]
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(b) Attention heat map of the sixth layer.
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[SEP]
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(c) Attention heat map of the final layer.
Fig. 2. Attention heat map of BERT on the BC5CDR-Chem dataset.
and LSTM seem not good at learning long-distance semantic
information. However, the performance of these three methods
on all the six datasets is inferior to BioBERT-MRC. BioBERT-
MRC can greatly improve the precision while maintaining
the recall, thereby improving model performance. The reason
may be that BioBERT-MRC can learn high-level semantic
information, thereby enhancing the model’s ability to identify
target entities. These experimental results show that BERT’s
ability to recognize biomedical entities in the MRC framework
TABLE VI
PERFORMANCE COMPARISON WITH OTHER EXISTING METHODS.
Method BC4CHEMD BC5CDR-Chem BC5CDR-Disease NCBI-Disease BC2GM JNLPBAP(%) R(%) F1(%) P(%) R(%) F1(%) P(%) R(%) F1(%) P(%) R(%) F1(%) P(%) R(%) F1(%) P(%) R(%) F1(%)
tmChem [2] 89.09 85.75 87.39∗∗ – – – – – – – – – – – – – – –
TaggerOne [3] – – – 94.20 88.80 91.40∗∗ 85.20 80.20 82.60∗∗ 85.10 80.80 82.90∗∗ – – – – – –
Lou et al. [4] – – – – – – 89.61 83.09 86.23∗∗ 90.72 74.89 82.05∗∗ – – – – – –
D3NER [8] – – – 93.73 92.56 93.14∗ 83.98 85.40 84.68∗∗ 85.03 83.80 84.41∗∗ – – – – – –
Luo et al. [9] 92.29 90.01 91.14∗∗ 93.49 91.68 92.57∗∗ – – – – – – – – – – – –
Sachan et al. [10] – – – – – – – – – 86.41 88.31 87.34∗∗ 81.81 81.57 81.69∗∗ 71.39 79.06 75.03∗∗
Wang et al. [11] 91.30 87.53 89.37∗∗ – – – – – – 85.86 86.42 86.14∗∗ 82.10 79.42 80.74∗∗ 70.91 76.34 73.52∗∗
Collabonet [12] 90.78 87.01 88.85∗∗ 94.26 92.38 93.31∗ 85.61 82.61 84.08∗∗ 85.48 87.27 86.36∗∗ 80.49 78.99 79.73∗∗ 74.43 83.22 78.58∗
BioBERT-Softmax [17] 92.80 91.92 92.36∗ 93.68 93.26 93.47∗ 86.47 87.84 87.15∗ 88.22 91.25 89.71∗ 84.32 85.12 84.72 72.24 83.56 77.49∗
BioBERT-MRC 92.83 91.94 92.38 94.37 94.00 94.19 87.42 87.30 87.36 89.67 90.42 90.04 86.05 83.94 84.98 75.96 82.13 78.93
Notes: The first part (i.e., row 13) is feature engineering-based methods, and the second part (i.e., row 410) is neural network-based methods. Both BioBERT-
Softmax and BioBERT-MRC are based on BioBERT v1.1 (+PubMed) [17]. ∗ and ∗∗ denote the method is significantly worse than BioBERT-MRC (p
<0.05 and p <0.01, respectively). The best scores are shown in bold, and the second best scores are underlined.
is superior to its ability to recognize biomedical entities in the
sequence labeling framework.
Then, we explored what the model has learned from each
layer of BERT, and why BERT can achieve better BioNER per-
formance in the MRC framework. Figure 2 shows the attention
heat map of BERT in the first layer, the middle layer (i.e., the
sixth layer), and the final layer. The first layer mainly encodes
the features of works/tokens, the middle layer tends to extract
syntactic information (e.g., phrases and segments), and the
final layer learns semantic information of the whole sequence.
Unlike sequence labeling problems that focus on the target
word/token and its surrounding words/tokens, MRC problems
often require more attention to the semantic information of
the entire sequence. Therefore, compared with using BERT in
the sequence labeling framework, performing it in the MRC
framework has more advantages in learning the syntactic and
semantic information of the dataset. This may be the reason
that BERT can obtain better BioNER performance in the MRC
framework.
D. Performance Comparison with Other Methods
Table VI shows the experimental results on BioNER
datasets. The first three methods all rely on feature engineer-
ing. TmChem [2] is a method that utilizes chemical knowledge
to design features to recognize chemical entities. TaggerOne
[3] and Lou’s model [4] both perform BioNER in a joint
manner with named entity normalization (NEN), in which the
feedback from NEN can be used to reduce NER errors. The
difference is the former uses a semi-Markov linear classifier
for BioNER, while the latter is based on a finite state machine.
However, these methods are often model- and entity-specific
and the performance is also unsatisfactory. In addition to the
first three methods, the others are all neural network-based
methods. Among these methods, the first five mainly use the
LSTM-CRF model, while the latter two leverage the BioBERT
model. D3NER [8] introduces various linguistic information to
improve performance. Luo et al. [9] utilized document-level
global information obtained by the attention mechanism to
enforce tagging consistency across multiple instances of the
same token in the document. Sachan et al. [10] trained a
bidirectional language model on unlabeled data and transfer
the weights to pre-train an BioNER model. Wang et al. [11]
proposed a multi-task learning framework for BioNER to
collectively use the training data of different types of entities.
CollaboNet [12] can also be regarded as a multi-task learn-
ing framework, which improves performance by combining
multiple BioNER models. Generally, the performance of these
LSTM-CRF-based models is superior to feature engineering-
based models. Most recently, Lee et al. [17] utilized BioBERT
to perform BioNER in the sequence labeling framework,
which raises the performance of BioNER to a new level.
We formulated the BioNER task as an MRC problem and
employed BERT to achieve BioNER in the MRC frame-
work. It is encouraging to see that BioBERT-MRC obtains
SOTA performance on all the six datasets. Compared with
feature engineering-based and LSTM-CRF-based methods, our
method usually obtains both the highest precision and recall
performance. This shows that our method is far superior to
those methods. Compared with BioBERT-Softmax, BioBERT-
MRC can greatly improve the precision, thereby increasing the
F1-score. This experimental result indicates that our method
is also superior to BioBERT-Softmax. In conclusion, these
experimental results show that BioBERT-MRC is superior in
performance as compared with other existing methods.
E. Case Study
To further explore the difference between BioBERT-MRC
and BioBERT-Softmax, we conducted the case study. The
results of case study are shown in Table VII. For the first
example, this is a case where BioBERT-Softmax recognized
false negatives (FNs) while BioBERT-MRC corrected them
as true positives (TPs). This example shows that BioBERT-
MRC has certain advantages over BioBERT-Softmax in terms
of learning syntactic information (e.g., phrases and segments).
The second example is a consistency problem. It can be seen
that BioBERT-Softmax only recognized one ‘cocaine’ in the
whole sequence, while BioBERT-MRC corrected the error of
BioBERT-Softmax. This example shows that BioBERT-MRC
can alleviate the problem of label inconsistency by learning the
semantic information of the entire sequence. The third and last
TABLE VII
REPRESENTATIVE RESULTS OF CASE STUDY.
No. Dataset Gold standard Model Result
1 BC4CHEMD lipoic acid(CHEMICAL)
BioBERT-Softmax · · · and the natural antioxidant lipoic acid , without influencing the levelof free · · ·
BioBERT-MRC · · · and the natural antioxidant lipoic acid , without influencing the levelof free · · ·
2 BC5CDR-Chem cocaine (CHEMICAL)DSE (OTHER)
BioBERT-Softmax · · · cocaine use , we conducted a pilot study to assess the safety of DSEin emergency department patients with cocaine - associated chest pain .
BioBERT-MRC · · · cocaine use , we conducted a pilot study to assess the safety of DSEin emergency department patients with cocaine - associated chest pain .
3 BC5CDR-Disease drug - induced disease(OTHER)
BioBERT-Softmax Differential diagnosis for drug - induced disease is invaluable even forpatients · · ·
BioBERT-MRC Differential diagnosis for drug - induced disease is invaluable even forpatients · · ·
4 NCBI Disease
dominantly inherited
neurodegeneration
(DISEASE)
BioBERT-Softmax This mutation may be valuable for developing models of dominantlyinherited neurodegeneration · · ·
BioBERT-MRC This mutation may be valuable for developing models of dominantlyinherited neurodegeneration · · ·
5 BC2GM RXR ligand bindingdomain (PROTEIN)
BioBERT-Softmax · · · influences the RXR ligand binding domain such that it is resistantto the binding of 9 - cis RA · · ·
BioBERT-MRC · · · influences the RXR ligand binding domain such that it is resistantto the binding of 9 - cis RA · · ·
6 JNLPBA
peroxisome proliferator -
activated receptor gamma
(OTHER)
BioBERT-Softmax Oxidized alkyl phospholipids are specific , high affinity peroxisomeproliferator - activated receptor gamma ligands and agonists .
BioBERT-MRC Oxidized alkyl phospholipids are specific , high affinity peroxisomeproliferator - activated receptor gamma ligands and agonists .
Notes: Green represents chemical entities, blue represents disease entities, and yellow represents protein entities.
examples are a case where BioBERT-Softmax recognized false
positives (FPs) while BioBERT-MRC corrected them as true
negatives (TNs). The fourth and fifth are segmentation problem
examples. Compared with BioBERT-Softmax, BioBERT-MRC
can better distinguish the boundary information of entities.
These four examples all demonstrate the effectiveness of
BioBERT-MRC in the syntactic learning.
Through the case study, we can infer that compared with
BioBERT-Softmax, BioBERT-MRC has better performance in
syntactic and semantic learning. Specifically, BioBERT-MRC
can correct some FNs and FPs, accurately recognize entity
boundaries, and alleviate the label inconsistency problem.
F. BioBERT-MRC for Transfer Learning
Transfer learning is an important method in NLP tasks.
Because similar datasets can be used for model training,
transfer learning may learn richer semantic knowledge. Among
the six datasets, BC4CHEMD and BC5CDR-Chem are both
chemical datasets, and BC4CHEMD has more annotated en-
tities. Therefore, we tried to use transfer learning to further
improve the performance of the model on the BC5CDR-
Chem dataset. Compared with directly using BERT to perform
BioNER on the BC5CDR-Chem dataset, using the weights
obtained from BC4CHEMD to perform transfer learning may
obtain better performance. As shown in Table V, BioBERT-
Softmax and BioBERT-MRC obtain F1-scores of 92.17%
and 92.38% on the BC4CHEMD dataset, respectively. We
used these two weights as the weights of BioBERT-Softmax
and BioBERT-MRC, and then performed transfer learning on
the BC5CDR-Chem dataset. The performance comparison is
illustrated in Table VIII. Directly using the BioBERT v1.1
(+PubMed) weight to perform NER on the BC5CDR-Chem
TABLE VIII
PERFORMANCE COMPARISON FOR TRANSFER LEARNING
Method Weight P(%) R(%) F1(%)
BioBERT-Softmax BioBERTv1.1(+PubMed) 92.64 94.39 93.51∗
BioBERT-Softmax BC4CHEMDa 93.85 94.15 94.00∗
BioBERT-MRC BioBERTv1.1(+PubMed) 94.37 94.00 94.19∗
BioBERT-MRC BC4CHEMDb 94.48 94.39 94.44
Notes: ∗ denotes the method is significantly worse than BioBERT-MRC
(p < 0.05). BioBERT v1.1 (+PubMed) can be obtained from Lee et al.
[17]. BC4CHEMDa and BC4CHEMDb are the weights from BioBERT-
Softmax and BioBERT-MRC on the BC4CHEMD dataset, respectively.
The best scores are shown in bold.
dataset, BioBERT-Softmax and BioBERT-MRC obtain 93.51%
and 94.19% respectively. On the contrary, using transfer learn-
ing, i.e., fine-tuning the weights obtained on the BC4CHEMD
dataset to recognize chemical entities on the BC5CDR-Chem
dataset, can achieve more excellent performance. By this way,
BioBERT-Softmax and BioBERT-MRC obtain F1-scores of
94.00% (+0.49% higher than 93.51%) and 94.44% (+0.25%
higher than 94.19%), respectively. These experimental results
show that compared with fine-tuning directly on the target
dataset, transfer learning can learn the knowledge of the source
dataset, thereby improving the performance of the model
on the target dataset. More importantly, the performance of
BioBERT-MRC is superior to BioBERT-Softmax in terms of
transfer learning. In the case of transfer learning, the F1-
score of BioBERT-Softmax is 94.00%, while the F1-score
of BioBERT-MRC is 94.44% (+0.44% higher than 94.00%).
The reason may be that BioBERT-MRC learns more semantic
information, which may be useful for transfer learning. This
experiment result indicates that BioBERT-MRC is more suit-
able for transfer learning than BioBERT-Softmax.
V. CONCLUSION
In this work, we use BERT to perform BioNER in the
MRC framework. Compared with using BERT in the sequence
labeling framework, performing it in the MRC framework can
introduce more prior knowledge by well-designed queries, and
no longer need decoding processes. The experimental results
demonstrate the effectiveness of our method. We also explore
the reasons for the excellent performance of BERT in the
MRC framework. Through experimental analysis, we infer
that BERT in the MRC framework has more advantages in
learning the syntactic and semantic information of the dataset.
Moreover, we further indicate the effectiveness of using BERT
in the framework for transfer learning, which may be valuable
for the development of BioNER tasks.
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